TAYSHA GENE THERAPIES INC (TSHA) Stock Overview
NASDAQ:TSHA - US8776191061 - Common Stock
TSHA Key Statistics, Chart & Performance
The current stock price of TSHA is 3.36 USD. In the past month the price increased by 19.57%. In the past year, price increased by 64.71%.
TSHA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.07 | 375.50B | ||
| AMGN | AMGEN INC | 13.01 | 152.70B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 142.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.56 | 60.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
| ARGX | ARGENX SE - ADR | 80.99 | 45.95B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.89 | 40.63B | ||
| INSM | INSMED INC | N/A | 30.67B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.03B | ||
| NTRA | NATERA INC | N/A | 23.06B | ||
| BIIB | BIOGEN INC | 8.79 | 20.62B |
Related stock screener links
About TSHA
Company Profile
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 73 full-time employees. The company went IPO on 2020-09-24. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The firm is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. The company has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
Company Info
TAYSHA GENE THERAPIES INC
3000 Pegasus Park Drive, Suite 1430
Dallas TEXAS 75247 US
CEO: RA Session
Employees: 73
Phone: 12146120000
TAYSHA GENE THERAPIES INC / TSHA FAQ
What is the stock price of TAYSHA GENE THERAPIES INC today?
The current stock price of TSHA is 3.36 USD. The price increased by 3.07% in the last trading session.
What is the ticker symbol for TAYSHA GENE THERAPIES INC stock?
The exchange symbol of TAYSHA GENE THERAPIES INC is TSHA and it is listed on the Nasdaq exchange.
On which exchange is TSHA stock listed?
TSHA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TAYSHA GENE THERAPIES INC stock?
18 analysts have analysed TSHA and the average price target is 8.84 USD. This implies a price increase of 163.1% is expected in the next year compared to the current price of 3.36. Check the TAYSHA GENE THERAPIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TAYSHA GENE THERAPIES INC worth?
TAYSHA GENE THERAPIES INC (TSHA) has a market capitalization of 916.57M USD. This makes TSHA a Small Cap stock.
How many employees does TAYSHA GENE THERAPIES INC have?
TAYSHA GENE THERAPIES INC (TSHA) currently has 73 employees.
What are the support and resistance levels for TAYSHA GENE THERAPIES INC (TSHA) stock?
TAYSHA GENE THERAPIES INC (TSHA) has a support level at 2.94. Check the full technical report for a detailed analysis of TSHA support and resistance levels.
Is TAYSHA GENE THERAPIES INC (TSHA) expected to grow?
The Revenue of TAYSHA GENE THERAPIES INC (TSHA) is expected to decline by -10.4% in the next year. Check the estimates tab for more information on the TSHA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TAYSHA GENE THERAPIES INC (TSHA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TSHA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TSHA, evaluating the profitability, health, valuation and growth aspects
- TAYSHA GENE THERAPIES INC (TSHA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TAYSHA GENE THERAPIES INC (TSHA) Sales and EPS estimates to see what analysts future expectations are.
- TAYSHA GENE THERAPIES INC (TSHA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TAYSHA GENE THERAPIES INC (TSHA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TAYSHA GENE THERAPIES INC (TSHA) Stock Chart to make your own analysis
- TAYSHA GENE THERAPIES INC (TSHA) Latest news and press-releases to stay up to date.
Does TAYSHA GENE THERAPIES INC (TSHA) stock pay dividends?
TSHA does not pay a dividend.
When does TAYSHA GENE THERAPIES INC (TSHA) report earnings?
TAYSHA GENE THERAPIES INC (TSHA) will report earnings on 2025-11-11, after the market close.
What is the Price/Earnings (PE) ratio of TAYSHA GENE THERAPIES INC (TSHA)?
TAYSHA GENE THERAPIES INC (TSHA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.34).
What is the Short Interest ratio of TAYSHA GENE THERAPIES INC (TSHA) stock?
The outstanding short interest for TAYSHA GENE THERAPIES INC (TSHA) is 15.02% of its float. Check the ownership tab for more information on the TSHA short interest.
TSHA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TSHA. When comparing the yearly performance of all stocks, TSHA is one of the better performing stocks in the market, outperforming 89.22% of all stocks.
TSHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TSHA. TSHA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TSHA Financial Highlights
Over the last trailing twelve months TSHA reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS decreased by -156.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.82% | ||
| ROE | -37.28% | ||
| Debt/Equity | 0.17 |
TSHA Forecast & Estimates
18 analysts have analysed TSHA and the average price target is 8.84 USD. This implies a price increase of 163.1% is expected in the next year compared to the current price of 3.36.
For the next year, analysts expect an EPS growth of -0.71% and a revenue growth -10.4% for TSHA